Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03195140 · ClinicalTrials.gov registry record · NA
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
A NA study of Diabetes Mellitus, Type 1, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
- 4
- Study locations
NCT03195140: Completed NA study of Diabetes Mellitus, Type 1, sponsored by Tandem Diabetes Care.
NCT03195140 is a NA study of Diabetes Mellitus, Type 1 that has completed, run by Tandem Diabetes Care. The registered enrollment target is 103 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03195140, a NA study of Diabetes Mellitus, Type 1, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
- 4
- Study locations
Study Summary
A 6-week crossover study will compare PLGS to SAP outcomes in adults and youth \> 6 years old with type 1 diabetes (T1D).
Primary Outcome
Percentage of time CGM \<70 mg/dL
Conditions Studied
Interventions
- DEVICE Predictive Low Glucose Suspend
Study Locations (4)
California
- Stanford University - Palo Alto
- William Sansum Diabetes Center - Santa Barbara
Colorado
- Barbara Davis Center - Aurora
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2017-08-11 |
| Est. Completion | 2018-02-06 |
| Phase | NA |
What the finished NCT03195140 record still lists
NCT03195140 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Predictive Low Glucose Suspend is the first listed.
NCT03195140 reports a single indexed study location in California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03195140 about?
NCT03195140 is a clinical study titled "Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial". A 6-week crossover study will compare PLGS to SAP outcomes in adults and youth \> 6 years old with type 1 diabetes (T1D).
What is the current status of trial NCT03195140?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2017-08-11. Estimated completion is 2018-02-06.
What conditions does trial NCT03195140 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03195140?
The interventions under investigation include: Predictive Low Glucose Suspend (DEVICE).
Who is sponsoring clinical trial NCT03195140?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03195140 being conducted?
This trial has 4 study locations across California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03195140's enrollment target sits among peer trials
103 49th of 118 higher than 70 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
RECRUITING · NA
-
National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.
RECRUITING · NA
-
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI